Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) …

Fatty acid β-oxidation (FAO) is the main bioenergetic pathway in human prostate cancer
(PCa) and a promising novel therapeutic vulnerability. Here we demonstrate therapeutic …

Metabolic reprogramming is associated with re/activation and antagonism of androgen
receptor (AR) signaling that drives prostate cancer (PCa) progression to castration …

Inhibition of the androgen receptor (AR) by second-generation anti-androgens is a standard
treatment for metastatic castration resistant prostate cancer (mCRPC), but it inevitably leads …

Androgen receptor (AR) signaling plays a central role in metabolic reprogramming for
prostate cancer (PCa) growth and progression. Mitochondria are metabolic powerhouses of …

Drug resistance of cancer cells is recognized as the primary cause of failure of
chemotherapeutic treatment in most human cancers. Growing evidences support the idea …

Androgen receptor (AR) is a transcriptional activator that, in prostate cells, stimulates gene
expression required for various cellular functions, including metabolisms and proliferation …

The androgen receptor (AR) plays a central role in prostate tumor growth. Inappropriate
reactivation of the AR after androgen deprivation therapy promotes development of …

Purpose: In this study, we addressed the underlying mechanisms for the association
between enzalutamide (ENZ) treatment and neuroendocrine prostate cancer (NEPC), and …

Castration and androgen receptor (AR) pathway inhibitors induce profound and sustained
responses in advanced prostate cancer. However, the inevitable recurrence is associated …